ReleaseWire

Choice Nutrition Supplements’ Raspberry Ketone Ultra has become one of the most highly reputable weight loss supplements online. Raspberry Ketone is a weight loss supplement which could greatly help people lose weight in a shorter amount of time compared to most weight loss products in the market. It is considered as one of the safest as well by many health experts. Raspberry which is a fruit usually used as a food additive and an ingredient for perfumes was found out to have properties that could hasten up the weight loss process naturally.

Asthma and allergic rhinitis are both very common diseases in the world today. As the global atmosphere becomes more and more seriously contaminated, incidence of these diseases increases year by year.

VitaBreeze is committed to providing consumers with safe dietary supplements. To ensure consumers have access to quality products that conform to the highest safety standards, the firm initiated a stringent third-party ISO testing process for each batch of its products.

Many women would like to get into shape effectively and this is why Venus Factor was created. Venus Factor is actually a program that says that it can transform the body of a woman into an hourglass figure. The weight loss system takes a much newer approach compared to the traditional weight loss programs. It is more focused on the shoulders and its core workouts involve building muscles. However, it does so while burning unwanted fats, which are why it is one of the most, talked about programs for weight loss across the world right now. This Venus Factor review will tell women whether or not this fat loss system is best for her.

There are over 30 million people suffering from seasonal asthma of different levels worldwide, and the situation is worse in deeply contaminated countries and regions with high tobacco consumption. Asthma and allergic rhinitis are both very common diseases in the world today. As the atmosphere becomes more seriously contaminated, incidence of these diseases increases year by year.

According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack.

In 2013, the diabetes prevalence rate of grown-ups aged in 20 to 79 was 8.3% in the globe. The number of sufferers reached 382 million. 80% of the patients lives in low to medium income countries. Meanwhile, the number of sufferers in these countries in increasing. The number of global diabetes sufferers is expected to be 592 million by 2035. In the current sufferer group, about 175 million people (46%) are not diagnosed or treated. In 2013, the global IGT prevalence rate was 6.9% and the number of sufferers was 316 million. The number is expected to be 474 million by 2035.

Tacrolimus, also named as "FK506" and "FR-900506", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade name "Prograf". Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It was approved by the FDA in 1994. Tacrolimus is sold in markets of several countries and regions now. In 1998, tacrolimus preparation (injection and capsule) was approved to import into China.

Pemetrexed, originally developed by Eli Lilly and Company, is a multi-targeted antimetabolite antitumor drug. This product is with huge growth potential in the market.

Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following symptoms: nausea; vomiting; and increased sensitivity to light, sound and smell (Bigal and Lipton, 2006). Because migraine is one of the most prevalent types of headache, there is a substantial economic and social burden associated with the condition worldwide, and it is therefore recognized as a high-priority public health problem by the World Health Organization (WHO) (Leonardi et al., 2005; Lusic, 2001). The Global Burden of Disease (GBD) study in 2010 ranks migraine as the first among the neurological disorders (Leonardi and Raggi, 2013).

A new, advanced medical imaging system by Bodkin Design and Engineering enables researchers to pinpoint data and analyze complex microscopic samples in real time. The VNIR-90 Hyperspectral Imager captures spectral images within fixed tissue or in-vivo biological samples, in a single video frame, for immediate identification and analysis.

Global Market Direct's pharmaceuticals report, "Lightlake Therapeutics Inc. - Product Pipeline Review - 2014" provides data on the Lightlake Therapeutics Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has become a heavy burden on individuals, families, society and governments.

Bevacizumab is an important kind of remedy for metastatic colon cancer, which belongs to humanized anti-VEGF monoclonal antibody. Approved by FDA, bevacizumab came into the market in 2004, with the brand name of "Avastin". Its main mechanism is to inhibit the function of a natural protein called vascular endothelial growth factor (VEGF) that stimulates new blood vessel formation through specific binding so as to stop or delay growth of blood vessels in tumor, disconnect the delivery of oxygen and other nutrition necessary in tumor cells' growth, as well as to improve the effect of chemotherapy remedy. Public data shows that the global sales value of bevacizumab in 2012 exceeded USD 6.3 billion, ranking the fourth among the 10 best selling monoclonal antibody drugs.

Garcinia Cambogia, the natural fat-buster, appetite suppressant, weight-loss supplement endorsed by national health experts and analysts and hailed as the Holy Grail of weight-loss is now available through the Golden Tree of Life Premium Strength Pure Garcinia Cambogia Lean in 180-count bottles. In honor of this launch, the Golden Tree of Life has a limited time offer to buy one 180-count bottle and receive a 60-count bottle free with a promotion code. Consumers must put both in the cart and use the promotion code “60FATBRN” in order to qualify for the promotion.

T3 Advisors, a global real estate consulting firm, today announced the addition of Kip Thompson as President of T3 Global Solutions as the company deepens its international reach. With more than 30 years of global executive leadership and corporate real estate experience, Kip will lead T3 Advisors’ global practice, enabling its clients to strategically and cost effectively expand to new and emerging markets.

Global Markets Direct's, 'Primary Dysmenorrhea - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Primary Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Dysmenorrhea. Primary Dysmenorrhea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Markets Direct's, 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Global Market Direct's pharmaceuticals report, "Mundipharma International Limited - Product Pipeline Review - 2014" provides data on the Mundipharma International Limited's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Project Synopsis:

Global Market Direct's pharmaceuticals report, "Upsher-Smith Laboratories, Inc. - Product Pipeline Review - 2014" provides data on the Upsher-Smith Laboratories, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Markets Direct's, 'Diabetic Gastroparesis - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Diabetic Gastroparesis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

GlobalData's clinical trial report, "Ichthyosis Vulgaris Global Clinical Trials Review, H1, 2014" provides data on the Ichthyosis Vulgaris clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ichthyosis Vulgaris. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ichthyosis Vulgaris. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Market Direct's pharmaceuticals report, "Array BioPharma Inc. - Product Pipeline Review - 2014" provides data on the Array BioPharma Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Unnecessary body fat can be stubborn to remove in a short period of time, which is exactly why individuals are recommended to go for products that can help them reduce weight without having to struggle too much in the long run. There are countless fat burner supplements in the market that have proved to be rather effective and one of these supplements includes Phen375.